Wegovy $25 a month: Cost, Coverage, and What You Really Need to Know

When you hear Wegovy, a prescription weight loss medication containing semaglutide, used to manage obesity in adults. Also known as semaglutide injection, it's one of the most talked-about drugs for weight loss in recent years. The idea of paying just $25 a month sounds almost too good to be true—and for most people, it is. The $25 price tag isn’t the actual cost of the drug. It’s a patient assistance program offer, usually tied to specific insurance plans or pharmacy coupons, like those from Express Scripts, a major pharmacy benefit manager in the U.S. that controls drug coverage for millions of insured patients. Without that help, Wegovy can cost over $1,300 a month out of pocket. So if you’re seeing $25 ads, ask: Who qualifies? What’s the catch? And does it even apply to you in India or elsewhere?

The real story behind Wegovy’s price isn’t about magic discounts—it’s about insurance rules, pharmacy networks, and how drug manufacturers play the system. Zepbound, another GLP-1 weight loss drug similar to Wegovy, but with a different active ingredient. and Ozempic, the same drug as Wegovy but approved for type 2 diabetes, not weight loss. are often confused with each other, but their coverage rules are wildly different. Insurance companies often deny Wegovy because they see obesity as a lifestyle issue, not a medical one. That’s why so many people end up fighting for approval, submitting letters of medical necessity, or paying full price until their plan changes. In the U.S., Express Scripts and other PBMs have started covering Wegovy more often in 2025, but only if you meet strict BMI thresholds, have related conditions like high blood pressure or diabetes, and prove you tried other methods first. In India, Wegovy isn’t even approved for sale yet, so the $25 offer doesn’t exist here—unless you’re importing it, which comes with legal and safety risks.

What you’ll find in the articles below isn’t just a list of prices. It’s the real-world breakdown of how people actually get access to these drugs. Some got coverage through employer plans. Others used patient support programs from Novo Nordisk, the maker of Wegovy. A few paid out of pocket and regretted it. There are stories of denials, appeals, and even doctors who helped patients jump through hoops to get approved. You’ll also see how these drugs connect to broader topics—like why insurance won’t cover weight loss meds, how they compare to older drugs like Saxenda, and what happens when you stop taking them. This isn’t marketing. It’s what people actually face when they try to get help with weight loss in today’s broken system. The $25 promise? It’s real—for a lucky few. For everyone else, the path is longer, messier, and far more complicated.